This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.82% per year. These returns cover a period from January 1, 1988 through October 5, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
ALNY Stock Down 25% Despite Q3 Earnings Beat on Demand Growth Concerns
by Zacks Equity Research
Alnylam's shares fall 25% despite Q3 beat as slower Amvuttra patient starts and demand concerns weigh on investor sentiment.
ALNYNegative Net Change REGNPositive Net Change NVSPositive Net Change RHHBYNegative Net Change
biotechnology biotechs medical pharmaceuticals
3 Promising Genomics Stocks to Add to Your Portfolio Now
by Ekta Bagri
Genomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.
ILMNNegative Net Change QURENegative Net Change TXGNegative Net Change BEAMNegative Net Change CRSPNegative Net Change
biotechnology biotechs genetics genomics medical pharmaceuticals
HALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Halozyme is poised for a Q3 earnings beat as strong demand for partnered drugs is likely to boost royalties and drive the top line.
HALONegative Net Change JNJNegative Net Change PFEPositive Net Change AMRXNegative Net Change
biotechs
VKTX Q3 Earnings Miss Estimates Amid Rising Clinical Expenses
by Zacks Equity Research
Viking Therapeutics' Q3 loss widens as rising costs weigh on results, while its obesity drug candidate advances through phase III studies.
VKTXNegative Net Change TGTXNegative Net Change AMRXNegative Net Change
biotechs earnings medical
GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth?
by Sundeep Ganoria
GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.
GSKNegative Net Change MRNANegative Net Change PFEPositive Net Change MRKNegative Net Change
biotechs medical messenger-rna pharmaceuticals vaccines
BMY Q3 Earnings Tops Estimates, Higher Charges Weigh on Outlook
by Zacks Equity Research
Bristol Myers tops Q3 earnings and revenue estimates as Growth Portfolio sales and Eliquis demand drive growth, but higher IPRD charges prompt a cut to 2026 EPS guidance.
BMYPositive Net Change PFEPositive Net Change BNTXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
BHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook Rises
by Zacks Equity Research
Bausch Health shares jump 9% as Q3 earnings top estimates, driven by Xifaxan-led Salix growth, improved profitability and raised 2026 guidance.
BHCNegative Net Change TGTXNegative Net Change IOVANegative Net Change AMRXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Recursion Pharmaceuticals to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
RXRX heads into Q3 earnings with key collaboration milestones, advancing clinical programs and upcoming pipeline updates that could shape its outlook.
RXRXNegative Net Change PFEPositive Net Change TGTXNegative Net Change IOVANegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
BIIB's Q3 Earnings Beat, New Drugs Aid Sales, '26 EPS View Tightened
by Zacks Equity Research
Biogen's Q3 earnings and revenues beat estimates as growth drugs drive sales, while the company tightens its 2026 adjusted EPS outlook amid rising costs.
BIIBNegative Net Change RHHBYNegative Net Change SUPNNo Net Change TGTXNegative Net Change
biotechs earnings
GSK Q3 Earnings Top Mark, Stock Down on Soft Vaccines Sales
by Zacks Equity Research
GSK's Q3 earnings beat estimates as HIV, oncology and respiratory medicines drive revenue growth, while declining vaccine sales weigh on shares.
GSKNegative Net Change JNJNegative Net Change TGTXNegative Net Change HRMYNegative Net Change
biotechs earnings